

## Shares issued and Cleansing Notice

20 December 2024

On 19 December 2024, 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) issued a total of 282,520 fully paid ordinary shares (**Shares**) under its Tax Exempt Employee Share Plan to qualifying employees.

### Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The *Corporations Act 2001 (Cth)* (**Corporations Act**) restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Corporations Act. By giving this notice, the issue of the 282,520 Shares to qualifying employees will fall within the exemption in section 708A(5) of the Corporations Act.

Pursuant to section 708A(5)(e) of the Corporations Act, the Company gives notice that:

1. The Company issued 282,520 ordinary shares on 19 December 2024 under its Tax Exempt Employee Share Plan to qualifying employees.
2. The Shares were issued without disclosure under Part 6D.2 Of the Corporations Act.
3. As at the date of this notice, the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (b) sections 674 and 674A of the Corporations Act.
3. As at the date of this notice, there is no information:
  - (a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - (b) that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of:
    - (i) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - (ii) the rights and liabilities attaching to the Shares.

–ENDS–

Authorised by the 4DMedical Board of Directors.

### Contacts

#### Corporate

Chief Financial Officer

Simon Glover

[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

#### Administration

Company Secretary

Naomi Lawrie

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)



## About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology<sup>®</sup>, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS<sup>®</sup>) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS<sup>™</sup>.

XV LVAS<sup>®</sup> and CT LVAS<sup>™</sup> reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity, and more personalised care for patients.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)